ArticleCancer imaging : the official publication of the International Cancer Imaging Society2023
Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Development and validation of a multivariable CT-based Delta-radiomics model for predicting efficacy to bevacizumab therapy in patients with colorectal liver metastases.Translational cancer research · 2026Article
- Role of spectral CT in quantitative evaluation of pathologic response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a pilot study.Journal of translational medicine · 2026Article
- Early prediction of response to chemotherapy with Cetuximab in colorectal liver metastasis with contrast-enhanced ultrasound perfusion analysis.BMC gastroenterology · 2026Article
- Spectral CT imaging in colorectal cancer: current applications, limitations, and future perspectives.Insights into imaging · 2026Review
- The diagnostic efficacy of venous-phase spectral CT combined with Node-RADS for differentiating enlarged lymph nodes in common solid tumors: a preliminary exploratory study.Frontiers in oncology · 2026Article
- Impact of primary colorectal cancer site on surgical outcomes for liver metastases: A retrospective study.World journal of gastrointestinal surgery · 2025Article
- Dual-layer spectral detector computed tomography in distinguishing between bland and neoplastic portal vein thrombosis.Quantitative imaging in medicine and surgery · 2025Article
- Dual-energy CT combined with histogram parameters in the assessment of perineural invasion in colorectal cancer.International journal of colorectal disease · 2025Article
- Assessment of Spectral Computed Tomography Image Quality and Detection of Lesions in the Liver Based on Image Reconstruction Algorithms and Virtual Tube Voltage.Diagnostics (Basel, Switzerland) · 2025Article
- Construction of a postoperative liver metastasis prediction model for colorectal cancer based on spectral CT imaging, CEA, and CA19-9.Translational cancer research · 2025Article
- Combination of single-source dual-energy computed tomography (CT) parameters and extracellular volume fraction for predicting lymphovascular and perineural invasion in colorectal cancer.Quantitative imaging in medicine and surgery · 2024Article
- Article
- Viscoelastic properties of colorectal liver metastases reflect tumour cell viability.Journal of translational medicine · 2024Article
- Application of spectral CT in diagnosis, classification and prognostic monitoring of gastrointestinal cancers: progress, limitations and prospects.Frontiers in molecular biosciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
Abstract
purposeEarly evaluation of the efficacy of first-line chemotherapy combined with bevacizumab in patients with colorectal cancer liver metastasis (CRLM) remains challenging. This study used 2-month post-chemotherapy spectral computed tomography (CT) to predict the overall survival (OS) and response of CRLM patients with bevacizumab-containing therapy.
methodThis retrospective analysis was performed in 104 patients with pathologically confirmed CRLM between April 2017 and October 2021. Patients were treated with 5-fluorouracil, leucovorin, oxaliplatin or irinotecan with bevacizumab. Portal venous phase spectral CT was performed on the target liver lesion within 2 months of commencing chemotherapy to demonstrate the iodine concentration (IoD) of the target liver lesion. The patients were classified as responders (R +) or non-responders (R -) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at 6 months. Multivariate analysis was performed to determine the relationships of the spectral CT parameters, tumor markers, morphology of target lesions with OS and response. The differences in portal venous phase spectral CT parameters between the R + and R - groups were analyzed. Receiver operating characteristic (ROC) curves were used to evaluate the predictive power of spectral CT parameters.
resultsOf the 104 patients (mean age ± standard deviation: 57.73 years ± 12.56; 60 men) evaluated, 28 (26.9%) were classified as R + . Cox multivariate analysis identified the iodine concentration (hazard ratio [HR]: 1.238; 95% confidence interval [95% CI]: 1.089-1.408; P < 0.001), baseline tumor longest diameter (BLD) (HR: 1.022; 95% CI: 1.005-1.038, P = 0.010), higher baseline CEA (HR: 1.670; 95% CI: 1.016-2.745, P = 0.043), K-RAS mutation (HR: 2.027; 95% CI: 1.192-3.449; P = 0.009), and metachronous liver metastasis (HR: 1.877; 95% CI: 1.179-2.988; P = 0.008) as independent risk factors for patient OS. Logistic multivariate analysis identified the IoD (Odds Ratio [OR]: 2.243; 95% CI: 1.405-4.098; P = 0.002) and clinical N stage of the primary tumor (OR: 4.998; 95% CI: 1.210-25.345; P = 0.035) as independent predictor of R + . Using IoD cutoff values of 4.75 (100ug/cm
conclusionsSpectral CT IoD can predict the OS and response of patients with CRLM after 2 months of treatment with bevacizumab-containing therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.